

## United States Patent and Trademark Office

D STATES DEPARTMENT OF COMME

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/748,484	12/29/2003	Darrell C. Conklin	97-72D1	9463
7590 08/31/2005		EXAMINER		
Shelby J. Walker			MERTZ, PREMA MARIA	
Patent Department ZymoGenetics, Inc.			ART UNIT	PAPER NUMBER
1201 Eastlake Avenue East			1646	
Seattle, WA 98102			DATE MAILED: 08/31/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/748,484	CONKLIN ET AL.
Office Action Summary	Examiner	Art Unit
	Prema M. Mertz	1646
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	nely filed /s will be considered timely. If the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on		
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	action is non-final.	
3) Since this application is in condition for alloward closed in accordance with the practice under E		
Disposition of Claims		
4) ☐ Claim(s) 1 and 2 is/are pending in the applicat 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-2 are subject to restriction and/or elements.	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine	er.	
10) The drawing(s) filed on is/are: a) acc	epted or b) objected to by the	Examiner.
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	• • • • • • • • • • • • • • • • • • • •	•
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)	·	
1) D Notice of References Cited (PTO-892)	4) Interview Summary	
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	Paper No(s)/Mail Di 5) Notice of Informal F 6) Other:	ate Patent Application (PTO-152)

U.S. Patent and Trademark Office
PTOL-326 (Rev. 1-04)

Application/Control Number: 10/748,484

Art Unit: 1646

## **DETAILED ACTION**

## Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Groups 1-24. Claims 1-2, are drawn to an antibody to a polypeptide of amino acid sequence as set forth in SEQ ID NO:2, 4, 12, 13, 19, 20, 25, 26, 34, 35, 14, 15, 16, 17, 21, 22, 23, 24, 27, 28, 29, 30, 31, or 32, classified in Class 530, subclass 387.9.

Should any one of the Groups from 1-24 be elected, Applicant is required to select one polypeptide (one amino acid sequence) as set forth in SEQ ID NO:2, 4, 12, 13, 19, 20, 25, 26, 34, 35, 14, 15, 16, 17, 21, 22, 23, 24, 27, 28, 29, 30, 31, or 32. Once one polypeptide sequence is selected, all other sequences will be withdrawn from consideration.

The inventions are distinct, each from the other because of the following reasons:

Inventions 1-24, are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention which cannot be exchanged. The antibodies of inventions 1-24 can be used to obtain the polynucleotides encoding the polypeptides, and can also be used in diagnostics, e.g. as a probe in immunoassays. Each of the specific polypeptides can be used to obtain the specific antibody, which binds to the polypeptide.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Application/Control Number: 10/748,484

Art Unit: 1646

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

## Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 August 17, 2005